Topic

Aetna (CVS Health)

A collection of 1351 issues

How to Get Gamifant (Emapalumab-lzsg) Covered by Aetna (CVS Health) in Pennsylvania: Prior Authorization, Appeals & Success Strategies

Answer Box: Getting Gamifant Covered by Aetna in Pennsylvania Aetna (CVS Health) requires prior authorization for Gamifant (emapalumab-lzsg) in Pennsylvania, with coverage limited to primary HLH patients who've failed conventional therapy. Success path: Have your hematologist submit PA documentation including HLH-2004 diagnostic criteria (genetic testing or 5+ clinical
6 min read

How to Get Defitelio (defibrotide) Covered by Aetna CVS Health in Washington: Complete Prior Authorization Guide

Quick Answer: Defitelio (defibrotide) requires prior authorization from Aetna CVS Health for FDA-approved hepatic VOD/SOS treatment post-HSCT. Submit clinical documentation showing VOD diagnosis plus renal/pulmonary dysfunction through CVS Specialty Pharmacy. If denied, use Washington's external review process within 180 days. Start by gathering transplant records, diagnosis
5 min read

How to Get Tremfya (Guselkumab) Covered by Aetna CVS Health in California: Prior Authorization, Appeals & Cost Savings

Answer Box: Fast Track to Tremfya Coverage Getting Tremfya (guselkumab) covered by Aetna CVS Health in California requires prior authorization through a dermatologist or rheumatologist. Submit documentation showing moderate-to-severe disease (≥10% body surface area or crucial areas affected) plus failure/intolerance of conventional treatments. First step: Have your specialist complete
6 min read

How to Get Keytruda (Pembrolizumab) Approved by Aetna CVS Health in Virginia: Complete Guide to Prior Authorization, Appeals, and Billing

Answer Box: Getting Keytruda Covered by Aetna CVS Health in Virginia Prior authorization is required for Keytruda (pembrolizumab) through Aetna CVS Health. Submit your request with complete clinical documentation including PD-L1 test results, pathology reports, and prior therapy records. If denied, Virginia's State Corporation Commission provides external review
5 min read